Clinical Pharmacology Clinical Trial
Official title:
A Randomized, Double-blind, Single-dose, 4 × 4 Crossover Phase I Study to Examine the Effects of TAK-233 on the Urethral Function in Healthy Female Subjects
The objective of this clinical trial is to examine the clinical pharmacology properties of TAK-233 in healthy female subjects
The primary objective of this study is to examine the pharmacodynamics and the safety of TAK-233 administered as a single dose in healthy women. ;
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02629562 -
Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02286518 -
TAK-114 Single- and Multiple-Dose Phase 1 Study
|
Phase 1 | |
Completed |
NCT01473108 -
Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862
|
Phase 1 | |
Completed |
NCT03424135 -
A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions
|
Phase 1 | |
Completed |
NCT05437094 -
Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740
|
Phase 1 | |
Completed |
NCT02276274 -
Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects
|
Phase 3 | |
Completed |
NCT03074058 -
Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet
|
Phase 1 | |
Completed |
NCT04511611 -
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects
|
Phase 1 | |
Completed |
NCT04511637 -
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects
|
Phase 1 | |
Completed |
NCT04364464 -
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
|
Phase 1 | |
Completed |
NCT06126861 -
The Mass Balance Study of LP-168 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03517943 -
A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT03136666 -
Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.
|
Phase 1 | |
Completed |
NCT03517930 -
A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT04366622 -
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight
|
Phase 1 |